Increase in nuclease resistance and incorporation of NF-κB decoy oligodeoxynucleotides by modification of the 3′-terminus

Journal of Gene Medicine

Volumn 9, Issue 9, 2007, Pages 812-819

  Osako, Mariana Kiomy ^a   Tomita, Naruya ^b   Nakagami, Hironori ^a   Kunugiza, Yasuo ^a   Yoshino, Masafumi ^a   Yuyama, Kazuhiko ^c   Tomita, Tetsuya ^a   Yoshikawa, Hideki ^a   Ogihara, Toshio ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c Gene Dsign Inc   (Japan)

Author keywords

Decoy; Gene therapy; NF B; ODN; Vascular smooth muscle cells

Indexed keywords

EXODEOXYRIBONUCLEASE III; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHODIESTERASE; PHOSPHOROTHIOIC ACID; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG STABILITY; ENZYME CONFORMATION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIGATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CELL SURVIVAL; EXODEOXYRIBONUCLEASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HELA CELLS; HUMANS; MATRIX METALLOPROTEINASE 9; MOLECULAR SEQUENCE DATA; MYOCYTES, SMOOTH MUSCLE; OLIGODEOXYRIBONUCLEOTIDES; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548569075     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1077     Document Type: Article

References (53)

1. Baeuerle PA, Baltimore D. NF-kappaB: ten years after. Cell 1996; 87: 13-20.
2. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
3. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/ NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 9: 2723-2735.
4. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-5799.
5. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998; 95: 729-7231.
6. Wang CY, Mayo MW, Komeluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683.
7. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
8. Berman KS, Verma UN, Harburg G, Minna JD, Cobb MH, Gaynor RB. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res 2002; 8: 354-360.
9. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-959.
10. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163-1174.
11. Kawamura I, Morishita R, Tsujimoto S, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 2001; 8: 905-912.
12. Miyake T, Aoki M, Nakashima H, et al. Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFkappaB and ets using chimeric decoy oligonucleotides in a rabbit model. Gene Ther 2006; 13: 695-704.
13. Nakashima H, Aoki M, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004; 109: 132-138.
14. Ono S, Date I, Onoda K, et al. Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy. Hum Gene Ther 1998; 9: 1003-1011.
15. Tomita N, Morishita R, Tomita S, et al. Inhibition of TNF-alpha, induced cytokine and adhesion molecule. Expression in glomerular cells in vitro and in vivo by transcription factor decoy for NFkappaB. Exp Nephrol 2001; 9: 181-190.
16. Yamasaki K, Asai T, Shimizu M, et al. Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 2003; 10: 356-364.
17. Yoshimura S, Morishita R, Hayashi K, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 2001; 8: 1635-1642.
18. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250: 997-1000.
19. Eckestein F. Phosphorothioate analogues of nucleotides - tools for the investigation of biochemical processes. Angew Chem 1983; 22: 423.
20. Miller PS, McParland KB, Jayaraman K, Ts'o PO. Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 1981; 20: 1874-1880.
21. Kume M, Komori K, Matsumoto T, et al. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation 2002; 105: 1226-1232.
22. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
23. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-899.
24. Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994; 269: 26801-26805.
25. Burgess TL, Fisher EF, Ross SL, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A 1995; 92: 4051-4055.
26. Gao WY, Han FS, Storm C, Egan W, Cheng YC. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 1992; 41: 223-229.
27. Hosoya T, Takeuchi H, Kanesaka Y, et al. Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 1999; 461: 136-140.
28. Gamper HB, Reed MW, Cox T, et al. Facile preparation of nuclease resistant 3′ modified oligodeoxynucleotides. Nucleic Acids Res 1993; 21: 145-150.
29. Hoshi S, Goto M, Koyama N, Nomoto K, Tanaka H. Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB. J Biol Chem 2000; 275: 883-889.
30. Abe T, Takai K, Nakada S, Yokota T, Takaku H. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides. FEBS Lett 1998; 425: 91-96.
31. Ahn JD, Morishita R, Kaneda Y, et al. Novel E217 decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Ther 2002; 9: 1682-1692.
32. Ahn JD, Morishita R, Kaneda Y, et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 2002; 90: 1325-1332.
33. Chu BC, Orgel LE. The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res 1992; 20: 5857-5858.
34. Park KK, Deok Ahn J, Lee IK, et al. Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP. Biochem Biophys Res Commun 2003; 308: 689-697.
35. Ahn JD, Kim CH, Magae J, et al. E217 decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem Biophys Res Commun 2003; 310: 1048-1053.
36. Gibson I. Antisense approaches to the gene therapy of cancer - 'Recnac'. Cancer Metastasis Rev 1996; 15: 287-299.
37. Henry SP, Bolte H, Auletta C, Kornbrust DJ. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 1997; 120: 145-155.
38. Srinivasan SK, Iversen P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 1995; 9: 129-137.
39. Iversen PL, Cornish KG, Iversen LJ, Mata JE, Bylund DB. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(l)-adrenergic receptor antagonists. Toxicol Appl Pharmacol 1999; 160: 289-296.
40. Henry SP, Giclas PC, Leeds J, et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997; 281: 810-816.
41. Crooke ST. Progress in antisense therapeutics. Hematol Pathol 1995; 9: 59-72.
42. Sawa Y, Morishita. R, Suzuki K. et al. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. Circulation 1997; 96(9 Suppl): II-280-4; discussion II-285.
43. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-1438.
44. Kutryk MJ, Foley DP, van den Brand M, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002; 39: 281-287.
45. Jun-Ichi S, Hiroshi I, Ryo G. Ryuichi M, Kensuke E, Mitsuaki I. Initial clinical cases of the use of a NF-kappaB decoy at the site of coronary stenting for the prevention of restenosis. Circ J 2004; 68: 270-271.
46. Nakamura H, Aoki M. Tamai K, et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 2002; 9: 1221-1229.
47. Agrawal S, Zhao Q, Jiang Z. et al. Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev 1997; 7: 575-584.
48. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994; 4: 201-206.
49. Henry SP, Monteith D, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997;12: 395-408.
50. Schechter PJ, Martin RR. Safety and tolerance of phosphorothiate in humans. In Antisense Research and Application, Crooke S (ed). Springer: New York, 1998; 233-241.
51. Chen TL, Miller PS, Ts'o PO, Colvin OM. Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single i.v. injection in mice. Drug Metab Dispos 1990; 18: 815-818.
52. Cossurn PA, Sasmor H, Dellinger D, et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 1993; 267: 1181-1190.
53. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 1991; 88: 7595-7599.